Anika Therapeutics (ANIK) Asset Writedowns and Impairment (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Asset Writedowns and Impairment of $1.5 million for Q2 2026, down 48.74% year-over-year from $3.0 million in Q2 2025, and up 49.52% quarter-over-quarter from $1.0 million in Q1 2026.
Anika Therapeutics (ANIK) Asset Writedowns and Impairment (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Asset Writedowns and Impairment for 17 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Asset Writedowns and Impairment fell 48.74% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $4.6 million (down 82.19% YoY), while the FY2025 annual figure was $5.8 million, down 86.98% from the prior year.
- Asset Writedowns and Impairment improved to $1.5 million in Q2 2026 per ANIK's latest filing, from $1.0 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $59.6 million in Q4 2023 and bottomed at $89000.0 in Q2 2022.
- Historically, Asset Writedowns and Impairment has averaged $5.8 million across 5 years, with a median of $1.1 million in 2025.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment jumped 3559.89% — and 2025, when it tumbled 95.43%.
- Anika Therapeutics' Asset Writedowns and Impairment stood at $1.6 million in 2022, then surged by 3559.89% to $59.6 million in 2023, then slumped by 68.73% to $18.6 million in 2024, then sank by 95.43% to $852000.0 in 2025, then jumped by 81.1% to $1.5 million in 2026.
- Business Quant data shows ANIK's Asset Writedowns and Impairment at $1.5 million in Q2 2026, $1.0 million in Q1 2026, and $852000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Mn |
| Jun 30, 2026 | 1.54 Mn |
| Mar 31, 2026 | 1.03 Mn |
| Mar 31, 2026 | 1.03 Mn |
| Dec 31, 2025 | 852,000.00 |
| Dec 31, 2025 | 852,000.00 |
| Sep 30, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Mar 31, 2025 | 832,000.00 |
| Mar 31, 2025 | 832,000.00 |
| Dec 31, 2024 | 18.63 Mn |
| Dec 31, 2024 | 18.63 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 675,000.00 |
| Jun 30, 2024 | 675,000.00 |
| Mar 31, 2024 | 2.06 Mn |
| Mar 31, 2024 | 2.06 Mn |